1/18/2013

Austrian drug firm Octapharma received approval from the FDA for its Octaplas plasma product for patients who lack enough clotting proteins. The product is made from human plasma that is treated to reduce the risk of viral transmission.

Full Story:
HealthDay News

Related Summaries